Strong Financial Outlook Signals Confidence in Oncology Portfolio Expansion
Exelixis is entering 2026 with momentum, supported by robust performance of its cabozantinib-based therapies and a robust research and clinical pipeline. The company’s recent announcement revealed preliminary, unaudited 2025 fiscal results and financial guidance for 2026, spotlighting continued revenue growth and anticipation for multiple product and pipeline milestones in the upcoming year.
Cabozantinib Franchise Continues to Dominate RCC and NET Markets
For fiscal 2025, Exelixis reported preliminary net product revenues of approximately $2.12 billion for its cabozantinib franchise—anchored by CABOMETYX® and COMETRIQ®. With 2026 net product revenue guidance set between $2.33 billion and $2.43 billion, the company expects further expansion, particularly as CABOMETYX retains its position as the leading oral therapy for renal cell carcinoma (RCC) and neuroendocrine tumors (NET).
Notably, the recent U.S. approval of CABOMETYX for new NET indications and strong 2L+ market performance underscore Exelixis’s continued dominance in key oncology segments. The company is also accelerating its gastrointestinal cancer sales efforts to leverage upcoming opportunities for zanzalintinib in GI cancers.
Zanzalintinib Regulatory Milestones Could Unlock New Commercial Avenues
Perhaps the biggest catalyst for Exelixis in 2026 could be the regulatory and clinical progress for zanzalintinib, its next-in-line franchise molecule. The FDA is currently reviewing the New Drug Application for zanzalintinib, in combination with atezolizumab, for previously treated metastatic colorectal cancer (CRC). The application is backed by positive phase 3 STELLAR-303 results showing significant survival benefits versus standard therapies.
Several pivotal trial milestones are expected:
- The final analysis of overall survival in the STELLAR-303 CRC study (mid-2026)
- Topline phase 3 results from the STELLAR-304 trial (mid-2026), evaluating zanzalintinib in previously untreated advanced non-clear cell RCC
- Ongoing enrollment for STELLAR-311, studying zanzalintinib as a first oral therapy in advanced NET
- The launch of additional studies, including LITESPARK-033 (in collaboration with Merck), STELLAR-316 (CRC, adjuvant setting), and STELLAR-201 (recurrent meningioma), all expected to begin or reach key milestones in 2026
Disciplined Investment in R&D and Strategic Cash Management Highlight Sustained Growth Ambitions
Exelixis projects a significant commitment to both R&D and shareholder returns in 2026. Research and development expenses are expected in the $875–$925 million range, funding expanded clinical programs and investments in next-generation therapies. The company’s stock repurchase program remains active, with $2.16 billion already deployed to buy back 76.7 million shares at $28.14 average per share, and an additional $750 million authorized for repurchases through the end of 2026.
Key Financial Figures at a Glance
| Metric | Fiscal Year 2025 | Fiscal Year 2026 Guidance |
|---|---|---|
| Total Revenues | $2.32 billion | $2.53–$2.63 billion |
| Net Product Revenues | $2.12 billion | $2.33–$2.43 billion |
| Cost of Goods Sold (% of Net Product Revenues) | 3.7% | 3.5%–4.5% |
| Research and Development Expenses | $825 million | $875–$925 million |
| Selling, General and Admin Expenses | $520 million | $575–$625 million |
| Ending Cash and Marketable Securities | $1.65 billion | n/p |
Multiple Clinical and Commercial Milestones on the Horizon
The year ahead could be transformative, with anticipated regulatory decisions, pivotal trial readouts, and significant investment in both pipeline assets and shareholder returns. If zanzalintinib secures FDA approval or reports additional strong data, it could establish Exelixis as a multi-franchise oncology leader.
Takeaway: A Company Poised for Next-Phase Oncology Growth
With a strong cash position, accelerating core product revenues, and a broad slate of trial milestones, Exelixis is positioning itself as a top contender in solid tumor oncology. Investors and the medical community may want to watch upcoming FDA decisions and pivotal trial releases closely—these could signal whether Exelixis maintains, or even accelerates, its upward trajectory through 2026 and beyond.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI